1
|
Behzadi Fard M, Kaviani S, Atashi A. Parvovirus B19 Infection in Human Bone Marrow Mesenchymal Stem Cells Affects Gene Expression of IL-6 and TNF-α and also Affects Hematopoietic Stem Cells Differentiation. Indian J Hematol Blood Transfus 2019; 35:765-772. [PMID: 31741634 DOI: 10.1007/s12288-019-01097-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2018] [Accepted: 02/07/2019] [Indexed: 12/24/2022] Open
Abstract
Parvovirus B19 (B19V) has been known to induce transient erythroid aplasia, cytopenia and aplastic anemia. This virus persists in bone marrow mesenchymal stem cells (HBMSCs) of some immunocompetent individuals several years after primary infection. In B19V infected erythroid progenitor cells, the virus induces transactivation of Interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) gene expression. Due the critical role of HBMSCs in bone marrow niche and inhibitory effect of inflammatory cytokines on hematopoiesis, the aim of this study was to investigate the effect of B19V on IL-6 and TNF-α gene expression intransfected cells. In addition we assessed the clonogenicity potential of cord blood CD34+ stem cells that were co-cultured with infected cells. After 24 h of transfection, quantitative mRNA expression of IL-6 and TNF-α was evaluated and human cord blood CD34+ HSC were cultured with the transfected cells. At the end of 7 days of culture, HSCs colony forming units (CFUs) assay was performed. Our findings demonstrated statistically significant (18.1 and 21.9 fold) increase of TNF-α and IL-6 gene expression respectively and decrease in burst forming unit-erythrocyte (BFU-E) and colony forming unit-erythrocyte (CFU-E) enumeration(p < 0.05). We concluded that, inducing inflammatory cytokines gene expression in B19V-infected HBMSCs might influence on bone marrow microenvironment and hematopoiesis.
Collapse
Affiliation(s)
- Mahin Behzadi Fard
- 1Department of Hematology and Blood Banking, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
| | - Saeid Kaviani
- 2Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
| | - Amir Atashi
- 3Stem Cell and Tissue Engineering Research Center, Shahroud University of Medical Sciences, Shahroud, Iran
| |
Collapse
|
2
|
Ryu HJ, Seo MR, Choi HJ, Ko KP, Park PW, Baek HJ. Mean platelet volume as a marker for differentiating disease flare from infection in Behçet's disease. Int J Rheum Dis 2016; 21:1640-1645. [PMID: 27886446 DOI: 10.1111/1756-185x.13008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
AIM The aim of this study was to investigate the association between mean platelet volume (MPV) and clinical manifestations, disease activity or infection in patients with Behçet's disease (BD). METHODS In total, 193 patients diagnosed with BD according to the international criteria for BD were enrolled. Demographic data, clinical manifestations and laboratory results were collected by medical interviews and reviewing medical records. RESULTS The female : male ratio was 2 : 1 and the age of symptom onset was 32.2 ± 11.1 years. The age at diagnosis of BD was 44.7 ± 11.1 years and the follow-up duration was 4.7 ± 3.8 years. MPV at diagnosis were significantly lower than of age and sex-matched controls (8.2 ± 1.2 vs. 8.6 ± 1.2 fL, P < 0.0001). Lower MPV was not related to organ involvement except skin diseases. During follow-up, MPV was lower in BD flare than in stable BD (8.2 ± 1.4 vs. 9.1 ± 1.4 fL, P < 0.0001) in the same patients. MPVs were significantly higher in cases of accompanying infections than in those with both BD flare and stable BD (9.3 ± 1.4 vs. 8.1 ± 1.3 fL, P = 0.018 and 9.7 ± 1.4 vs. 8.8 ± 1.0 fL, P = 0.001, respectively). CONCLUSIONS MPV was significantly lower in patients with BD than controls. MPV declined in BD flare and increased in cases of infection in same patients. MPV may be useful as a marker of BD activity and its monitoring can be helpful for differentiating BD flare from infection in BD patients.
Collapse
Affiliation(s)
- Hee Jung Ryu
- Department of Rheumatology, Gachon University Gil Medical Center, Incheon, Korea
| | - Mi Ryoung Seo
- Department of Rheumatology, Gachon University Gil Medical Center, Incheon, Korea
| | - Hyo Jin Choi
- Department of Rheumatology, Gachon University Gil Medical Center, Incheon, Korea
| | - Kwang-Pil Ko
- Department of Preventive Medicine, Gachon University Gil Medical Center, Incheon, Korea
| | - Pil Whan Park
- Department of Laboratory Medicine, Gachon University Gil Medical Center, Incheon, Korea
| | - Han Joo Baek
- Department of Rheumatology, Gachon University Gil Medical Center, Incheon, Korea
| |
Collapse
|
3
|
Ghang B, Kwon O, Hong S, Lee CK, Yoo B, Kim YG. Neutrophil-to-lymphocyte ratio is a reliable marker of treatment response in rheumatoid arthritis patients during tocilizumab therapy. Mod Rheumatol 2016; 27:405-410. [DOI: 10.1080/14397595.2016.1214340] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- Byeongzu Ghang
- Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - Ohchan Kwon
- Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - Seokchan Hong
- Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - Chang-Keun Lee
- Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - Bin Yoo
- Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - Yong-Gil Kim
- Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| |
Collapse
|
4
|
Gavito AL, Cabello R, Suarez J, Serrano A, Pavón FJ, Vida M, Romero M, Pardo V, Bautista D, Arrabal S, Decara J, Cuesta AL, Valverde AM, Rodríguez de Fonseca F, Baixeras E. Single administration of recombinant IL-6 restores the gene expression of lipogenic enzymes in liver of fasting IL-6-deficient mice. Br J Pharmacol 2016; 173:1070-84. [PMID: 26750868 DOI: 10.1111/bph.13423] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2015] [Revised: 12/18/2015] [Accepted: 01/06/2016] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND AND PURPOSE Lipogenesis is intimately controlled by hormones and cytokines as well as nutritional conditions. IL-6 participates in the regulation of fatty acid metabolism in the liver. We investigated the role of IL-6 in mediating fasting/re-feeding changes in the expression of hepatic lipogenic enzymes. EXPERIMENTAL APPROACH Gene and protein expression of lipogenic enzymes were examined in livers of wild-type (WT) and IL-6-deficient (IL-6(-/-) ) mice during fasting and re-feeding conditions. Effects of exogenous IL-6 administration on gene expression of these enzymes were evaluated in vivo. The involvement of STAT3 in mediating these IL-6 responses was investigated by using siRNA in human HepG2 cells. KEY RESULTS During feeding, the up-regulation in the hepatic expression of lipogenic genes presented similar time kinetics in WT and IL-6(-/-) mice. During fasting, expression of lipogenic genes decreased gradually over time in both strains, although the initial drop was more marked in IL-6(-/-) mice. Protein levels of hepatic lipogenic enzymes were lower in IL-6(-/-) than in WT mice at the end of the fasting period. In WT, circulating IL-6 levels paralleled gene expression of hepatic lipogenic enzymes. IL-6 administration in vivo and in vitro showed that IL-6-mediated signalling was associated with the up-regulation of hepatic lipogenic enzyme genes. Moreover, silencing STAT3 in HepG2 cells attenuated IL-6 mediated up-regulation of lipogenic gene transcription levels. CONCLUSIONS AND IMPLICATIONS IL-6 sustains levels of hepatic lipogenic enzymes during fasting through activation of STAT3. Our findings indicate that clinical use of STAT3-associated signalling cytokines, particularly against steatosis, should be undertaken with caution.
Collapse
Affiliation(s)
- A L Gavito
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain.,UGC-Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - R Cabello
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain
| | - J Suarez
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain.,UGC-Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - A Serrano
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain.,UGC-Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - F J Pavón
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain.,UGC-Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - M Vida
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain.,UGC-Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - M Romero
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain
| | - V Pardo
- Instituto de Investigaciones Biomédicas Alberto Sols (CSIC/UAM), Madrid, 28029, Spain.,Ciber de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, 28029, Spain
| | - D Bautista
- Unidad de Gestión Clínica de Anatomía Patológica, Hospital Regional Universitario de Málaga, Málaga 29010, Spain
| | - S Arrabal
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain.,UGC-Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - J Decara
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,UGC-Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - A L Cuesta
- Danish Diabetes Academy, Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, Denmark
| | - A M Valverde
- Instituto de Investigaciones Biomédicas Alberto Sols (CSIC/UAM), Madrid, 28029, Spain.,Ciber de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, 28029, Spain
| | - F Rodríguez de Fonseca
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain.,UGC-Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain
| | - E Baixeras
- Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga (IBIMA)/Universidad de Málaga, Málaga, 29010, Spain.,Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain.,UGC-Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain
| |
Collapse
|
5
|
Mean Platelet Volume and Splenomegaly as Useful Markers of Subclinical Activity in Egyptian Children with Familial Mediterranean Fever: A Cross-Sectional Study. Int J Chronic Dis 2015; 2015:152616. [PMID: 26464867 PMCID: PMC4590932 DOI: 10.1155/2015/152616] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Revised: 06/27/2015] [Accepted: 07/05/2015] [Indexed: 11/17/2022] Open
Abstract
Objective. To study whether mean platelet volume (MPV) and splenomegaly could be used as subclinical inflammatory markers in children with familial Mediterranean fever (FMF) at the attack-free period. Patients and Methods. The study included ninety-seven children with FMF. MPV was carried out within 4 hours of blood sampling according to standard laboratory practice. Splenomegaly was determined by abdominal ultrasound (USG). Results. High MPV was detected in 84.45% of our studied patients and was significantly higher in FMF patients with splenomegaly than in patients without splenomegaly. There was a statistically significant correlation between MPV and splenic span (P = 0.045). Conclusion. Elevated MPV and its significant correlation with splenic span in FMF children during the attack-free periods support the use of MPV and splenomegaly as useful markers of the subclinical inflammation in FMF patients at the attack-free period.
Collapse
|
6
|
Sert A, Kilicaslan C, Solak ES, Arslan S. Mean platelet volume in children with Reye-like syndrome. Platelets 2015; 26:212-5. [DOI: 10.3109/09537104.2013.795648] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
7
|
Evaluation of the Mean Platelet Volume and Red Cell Distribution Width in FMF: Are They Related to Subclinical Inflammation or Not? Int J Chronic Dis 2014; 2014:127426. [PMID: 26464849 PMCID: PMC4590920 DOI: 10.1155/2014/127426] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2013] [Revised: 02/02/2014] [Accepted: 02/05/2014] [Indexed: 11/18/2022] Open
Abstract
In this paper we want to demonstrate whether higher than normal levels of RDW, and lower than normal levels of MPV can be used as indicators of subclinical inflammation and tools for treatment decision in FMF or not. The participants in this study included 89 patients with FMF during attack-free periods and 30 healthy controls. The RDW and platelet counts were significantly higher, while the MPV was significantly lower in the patients with FMF group than healthy control group (P < 0.001; P = 0.005; P < 0.001, resp.). In the attack-free FMF group, a negative correlation was found between the MPV and RDW values (P < 0.001, r = −0.40). The positive correlation was found between the RDW and ESR (r = 0.23, P = 0.028). And the negative correlation was found between the MPV and CRP (r = −0.216, P = 0.042). Consequently, our results suggest that low MPV and high RDW levels may provide additional information about subclinical inflammation in FMF patients. But other strong predisposing factors affecting subclinical inflammation in FMF should be considered. Further studies with large numbers of patients are needed. Treatment of FMF should include not only prevention of acute attacks but also decreasing of the subclinical inflammation.
Collapse
|
8
|
Gaberman E, Pinzur L, Levdansky L, Tsirlin M, Netzer N, Aberman Z, Gorodetsky R. Mitigation of Lethal Radiation Syndrome in Mice by Intramuscular Injection of 3D Cultured Adherent Human Placental Stromal Cells. PLoS One 2013; 8:e66549. [PMID: 23823334 PMCID: PMC3688917 DOI: 10.1371/journal.pone.0066549] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2012] [Accepted: 05/12/2013] [Indexed: 12/22/2022] Open
Abstract
Exposure to high lethal dose of ionizing radiation results in acute radiation syndrome with deleterious systemic effects to different organs. A primary target is the highly sensitive bone marrow and the hematopoietic system. In the current study C3H/HeN mice were total body irradiated by 7.7 Gy. Twenty four hrs and 5 days after irradiation 2×106 cells from different preparations of human derived 3D expanded adherent placental stromal cells (PLX) were injected intramuscularly. Treatment with batches consisting of pure maternal cell preparations (PLX-Mat) increased the survival of the irradiated mice from ∼27% to 68% (P<0.001), while cell preparations with a mixture of maternal and fetal derived cells (PLX-RAD) increased the survival to ∼98% (P<0.0001). The dose modifying factor of this treatment for both 50% and 37% survival (DMF50 and DMF37) was∼1.23. Initiation of the more effective treatment with PLX-RAD injection could be delayed for up to 48 hrs after irradiation with similar effect. A delayed treatment by 72 hrs had lower, but still significantly effect (p<0.05). A faster recovery of the BM and improved reconstitution of all blood cell lineages in the PLX-RAD treated mice during the follow-up explains the increased survival of the cells treated irradiated mice. The number of CD45+/SCA1+ hematopoietic progenitor cells within the fast recovering population of nucleated BM cells in the irradiated mice was also elevated in the PLX-RAD treated mice. Our study suggests that IM treatment with PLX-RAD cells may serve as a highly effective “off the shelf” therapy to treat BM failure following total body exposure to high doses of radiation. The results suggest that similar treatments may be beneficial also for clinical conditions associated with severe BM aplasia and pancytopenia.
Collapse
Affiliation(s)
- Elena Gaberman
- Sharett Institute of Oncology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel
| | | | - Lilia Levdansky
- Sharett Institute of Oncology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel
| | - Maria Tsirlin
- Sharett Institute of Oncology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel
| | - Nir Netzer
- Pluristem Therapeutics Inc., Haifa, Israel
| | | | - Raphael Gorodetsky
- Sharett Institute of Oncology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel
- * E-mail:
| |
Collapse
|
9
|
Erdem E, Erdem D, Dilek M, Kaya C, Karataş A, Kut E, Çoban M, Cengiz K, Arιk N, Akpolat T. Red cell distribution width and mean platelet volume in amyloidosis. Clin Appl Thromb Hemost 2012; 20:334-7. [PMID: 23076775 DOI: 10.1177/1076029612462761] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
We aimed to determine whether red cell distribution width (RDW) and mean platelet volume (MPV) values differ between patients with reactive amyloid A (AA) amyloidosis due to chronic inflammatory disease and in healthy participants. In this study, 33 patients with AA amyloidosis and 40 age- and sex-matched healthy controls were enrolled. Erythrocyte sedimentation rate (ESR), RDW, platelet count (PLT), and MPV levels were retrospectively obtained from our computerized patient database. We found RDW, ESR, and PLT levels to be significantly higher in patients with AA amyloidosis compared with the controls (P < .0001). Mean platelet volume was significantly lower in patients with amyloidosis (P < .0001). Inflammatory diseases such as AA amyloidosis may demonstrate low MPV and high RDW levels.
Collapse
Affiliation(s)
- Emre Erdem
- 1Department of Nephrology, Faculty of Medicine, Ondokuz Mayıs University, Samsun, Turkey
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Association Between Platelet Count and Components of Metabolic Syndrome in Geriatric Taiwanese Women. INT J GERONTOL 2012. [DOI: 10.1016/j.ijge.2012.01.015] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
11
|
Chang YL, Pei C, Pei D, Tang SH, Hsu CH, Chen YL, Hsia TL, Lin JD, Wu CZ, Chang JB. Association Between Platelet Count and Components of Metabolic Syndrome in Geriatric Taiwanese Males. INT J GERONTOL 2012. [DOI: 10.1016/j.ijge.2012.01.021] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
12
|
Abstract
Acute rheumatic fever (ARF) is still an endemic disease, especially among school-aged children in developing countries. Mean platelet volume (MPV), which is commonly used as a measure of platelet size, indicates the rate of platelet production and platelet activation. We aimed to investigate MPV in children with ARF. The study population consisted of 40 children with ARF (32 patients with carditis and 8 patients without carditis) and 40 healthy control subjects. White blood cell (WBC) and platelet counts were significantly higher and MPV values were significantly lower in patients with ARF during the acute stage when compared to controls. Erythrocyte sedimentation rate (ESR) and C-reactive protein values significantly decreased in patients with ARF after the treatment when compared to baseline, whereas MPV values increased. MPV values were negatively correlated with ESR and WBC, and platelet counts. In conclusion, during the acute stage of ARF, MPV values were lower when compared to controls.
Collapse
Affiliation(s)
- Ahmet Sert
- Department of Pediatric Cardiology, Konya Training and Research Hospital, Konya, Turkey.
| | | | | |
Collapse
|
13
|
Sahin S, Senel S, Ataseven H, Yalcin I. Does mean platelet volume influence the attack or attack-free period in the patients with Familial Mediterranean fever? Platelets 2012; 24:320-3. [PMID: 22720903 DOI: 10.3109/09537104.2012.697591] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Familial Mediterranean fever (FMF) is an autosomal recessive hereditary disease which is characterized by recurrent attacks of fever and peritonitis, pleuritis, arthritis, or erysipelas-like skin disease. Mean platelet volume (MPV) is a sign of platelet activation. There are limited studies in the literature about MPV levels in FMF patients. We aimed to investigate MPV levels during the attack period (group 1) and attack-free periods (group 2) in FMF patients, and to compare them with healthy controls (group 3). The study consisted of the data of: 60 group 1 patients, 120 group 2 patients, and 75 group 3 patients. Erythrocyte sedimentation rate, C-reactive protein, white blood cell count, platelet count, and MPV levels were retrospectively recorded from patient files. Statistical analyses showed that MPV was significantly lower in FMF patients both in group 1 and group 2 than in group 3 (p = 0.004, p = 0.002, respectively); however, there was no difference among group 1 and group 2 in patients with FMF (p = 0.279). The mean platelet count of group 1 was higher than that of group 3 (p = 0.010). In conclusion, this study results suggested that MPV level did not increase on the contrary, it decreased in patients with FMF both in group 1 and/or group 2 when compared to group 3. It was concluded that the lower MPV level was an expected result of secondary thrombocytosis in FMF patients.
Collapse
Affiliation(s)
- Safak Sahin
- Department of Internal Medicine, Medicine Faculty, Gaziosmanpasa University, Tokat, Turkey.
| | | | | | | |
Collapse
|
14
|
Evaluation of the mean platelet volume in children with familial Mediterranean fever. Rheumatol Int 2011; 32:3559-63. [PMID: 22086472 DOI: 10.1007/s00296-011-2251-x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2011] [Accepted: 10/22/2011] [Indexed: 12/15/2022]
|
15
|
Maughan TS. The treatment of patients with low tumour burden and/or slow growing disease. Eur J Cancer 2011; 47 Suppl 3:S67-75. [PMID: 21944032 DOI: 10.1016/s0959-8049(11)70149-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Timothy S Maughan
- Gray Institute of Radiation Oncology and Biology, Oxford University, Oxford, United Kingdom
| |
Collapse
|
16
|
Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, Rogers P, Wasan H, Falk S, Gollins S, Hickish T, Bessell EM, Propper D, Kennedy MJ, Kaplan R, Maughan TS. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011; 12:642-53. [PMID: 21641867 PMCID: PMC3159416 DOI: 10.1016/s1470-2045(11)70102-4] [Citation(s) in RCA: 194] [Impact Index Per Article: 14.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
BACKGROUND When cure is impossible, cancer treatment should focus on both length and quality of life. Maximisation of time without toxic effects could be one effective strategy to achieve both of these goals. The COIN trial assessed preplanned treatment holidays in advanced colorectal cancer to achieve this aim. METHODS COIN was a randomised controlled trial in patients with previously untreated advanced colorectal cancer. Patients received either continuous oxaliplatin and fluoropyrimidine combination (arm A), continuous chemotherapy plus cetuximab (arm B), or intermittent (arm C) chemotherapy. In arms A and B, treatment continued until development of progressive disease, cumulative toxic effects, or the patient chose to stop. In arm C, patients who had not progressed at their 12-week scan started a chemotherapy-free interval until evidence of disease progression, when the same treatment was restarted. Randomisation was done centrally (via telephone) by the MRC Clinical Trials Unit using minimisation. Treatment allocation was not masked. The comparison of arms A and B is described in a companion paper. Here, we compare arms A and C, with the primary objective of establishing whether overall survival on intermittent therapy was non-inferior to that on continuous therapy, with a predefined non-inferiority boundary of 1.162. Intention-to-treat (ITT) and per-protocol analyses were done. This trial is registered, ISRCTN27286448. FINDINGS 1630 patients were randomly assigned to treatment groups (815 to continuous and 815 to intermittent therapy). Median survival in the ITT population (n=815 in both groups) was 15.8 months (IQR 9.4-26.1) in arm A and 14.4 months (8.0-24.7) in arm C (hazard ratio [HR] 1.084, 80% CI 1.008-1.165). In the per-protocol population (arm A, n=467; arm C, n=511), median survival was 19.6 months (13.0-28.1) in arm A and 18.0 months (12.1-29.3) in arm C (HR 1.087, 0.986-1.198). The upper limits of CIs for HRs in both analyses were greater than the predefined non-inferiority boundary. Preplanned subgroup analyses in the per-protocol population showed that a raised baseline platelet count, defined as 400,000 per μL or higher (271 [28%] of 978 patients), was associated with poor survival with intermittent chemotherapy: the HR for comparison of arm C and arm A in patients with a normal platelet count was 0.96 (95% CI 0.80-1.15, p=0.66), versus 1.54 (1.17-2.03, p=0.0018) in patients with a raised platelet count (p=0.0027 for interaction). In the per-protocol population, more patients on continuous than on intermittent treatment had grade 3 or worse haematological toxic effects (72 [15%] vs 60 [12%]), whereas nausea and vomiting were more common on intermittent treatment (11 [2%] vs 43 [8%]). Grade 3 or worse peripheral neuropathy (126 [27%] vs 25 [5%]) and hand-foot syndrome (21 [4%] vs 15 [3%]) were more frequent on continuous than on intermittent treatment. INTERPRETATION Although this trial did not show non-inferiority of intermittent compared with continuous chemotherapy for advanced colorectal cancer in terms of overall survival, chemotherapy-free intervals remain a treatment option for some patients with advanced colorectal cancer, offering reduced time on chemotherapy, reduced cumulative toxic effects, and improved quality of life. Subgroup analyses suggest that patients with normal baseline platelet counts could gain the benefits of intermittent chemotherapy without detriment in survival, whereas those with raised baseline platelet counts have impaired survival and quality of life with intermittent chemotherapy and should not receive a treatment break. FUNDING Cancer Research UK.
Collapse
Affiliation(s)
| | - Angela M Meade
- Medical Research Council Clinical Trials Unit, London, UK
| | | | | | - Ayman Madi
- School of Medicine, Cardiff University, Cardiff, UK
| | - David Fisher
- Medical Research Council Clinical Trials Unit, London, UK
| | - Sarah L Kenny
- Medical Research Council Clinical Trials Unit, London, UK
| | - Edward Kay
- Medical Research Council Clinical Trials Unit, London, UK
| | | | - Malcolm Pope
- Patient Representative, Velindre Cancer Centre, Cardiff, UK
| | | | | | - Stephen Falk
- Bristol Haematology and Oncology Centre, Bristol, UK
| | | | - Tamas Hickish
- Bournemouth and Poole Hospitals and Bournemouth University, Bournemouth, UK
| | | | | | - M John Kennedy
- ICORG, All Ireland Co-operative Oncology Research Group, Dublin, Ireland
| | - Richard Kaplan
- Medical Research Council Clinical Trials Unit, London, UK
| | | | - on behalf of the MRC COIN Trial Investigators
- School of Medicine, Cardiff University, Cardiff, UK
- Medical Research Council Clinical Trials Unit, London, UK
- St James's University Hospital and University of Leeds, Leeds, UK
- Queens University Belfast, Belfast, UK
- Weston Park Hospital, Sheffield, UK
- Patient Representative, Velindre Cancer Centre, Cardiff, UK
- Charing Cross Hospital, London, UK
- Hammersmith Hospital, London, UK
- Bristol Haematology and Oncology Centre, Bristol, UK
- Glan Clwyd Hospital, Rhyl, UK
- Bournemouth and Poole Hospitals and Bournemouth University, Bournemouth, UK
- Nottingham City Hospital, Nottingham, UK
- St Bartholomew's Hospital, London, UK
- ICORG, All Ireland Co-operative Oncology Research Group, Dublin, Ireland
| |
Collapse
|
17
|
Makay B, Türkyilmaz Z, Duman M, Unsal E. Mean platelet volume in Henoch-Schönlein purpura: relationship to gastrointestinal bleeding. Clin Rheumatol 2009; 28:1225-8. [PMID: 19543767 DOI: 10.1007/s10067-009-1219-7] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2009] [Revised: 06/07/2009] [Accepted: 06/08/2009] [Indexed: 11/24/2022]
Abstract
Henoch-Schönlein purpura (HSP) is the most common systemic vasculitis in children. Gastrointestinal (GI) bleeding is one of the major complications affecting one third of the cases which may cause serious morbidity. Platelet volume directly correlates with the platelet function and activation. Small platelets have lower functional capabilities than larger ones. The aim of this retrospective study was to evaluate levels of mean platelet volume (MPV) in patients with HSP compared with healthy controls and to investigate the relationship between MPV and gastrointestinal bleeding. The study consisted of 43 HSP patients (male/female = 25/18, mean age = 6.2 +/- 2.6 years) and 27 age-matched healthy children (male/female = 14/13, mean age = 6.9 +/- 2 years) as control group. HSP patients had significantly lower MPV levels than healthy controls (7.5 +/- 0.8 vs. 7.9 +/- 0.5, p = 0.027). Thirteen of 43 patients had gastrointestinal bleeding. MPV was significantly lower in patients with GI bleeding than patients without bleeding (7.0 +/- 0.8 vs. 7.7 +/- 0.6, p = 0.01). Platelet counts, white blood cell counts, and C-reactive protein levels were significantly higher in patients with GI bleeding when compared to patients without GI bleeding (p = 0.03, p = 0.004, and p = 0.03, respectively). This study suggests that low MPV may contribute to GI bleeding in HSP.
Collapse
Affiliation(s)
- Balahan Makay
- Department of Pediatrics, Division of Pediatric Immunology and Rheumatology, Dokuz Eylul University Hospital, 35340, Balçova, Izmir, Turkey.
| | | | | | | |
Collapse
|
18
|
Makay B, Türkyilmaz Z, Ünsal E. Mean platelet volume in children with familial Mediterranean fever. Clin Rheumatol 2009; 28:975-8. [DOI: 10.1007/s10067-009-1148-5] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2009] [Accepted: 02/25/2009] [Indexed: 10/21/2022]
|
19
|
Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003; 103:642-6. [PMID: 12494472 DOI: 10.1002/ijc.10833] [Citation(s) in RCA: 297] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Interleukin-6 (IL-6) is a multifunctional cytokine produced by macrophages, T cells, B cells, endothelial cells and tumour cells. Interleukin-6 is able to promote tumour growth by upregulating anti-apoptotic and angiogenic proteins in tumour cells. In murine models it has been demonstrated that antibodies against IL-6 diminish tumour growth. Several reports have highlighted the prognostic importance of IL-6 in e.g., prostate and colon cancer. We addressed prospectively the prognostic significance of serum IL-6 (sIL-6), measured at diagnosis of metastasis, in 96 unselected and consecutive patients with progressive metastatic breast cancer before the initiation of systemic therapy. The median sIL-6 value for the breast cancer population was 6.6 +/- 2.1 pg/ml. Patients with 2 or more metastatic sites had higher sIL-6 values compared to those with only 1 metastatic site (respectively 8.15 +/- 1.7 pg/ml and 3.06 +/- 6.6 pg/ml; p < 0.001). Patients with liver metastasis (8.3 +/- 2.4 pg/ml), with pleural effusions (10.65 +/- 9.9 pg/ml) and with dominant visceral disease (8.15 +/- 3.3 pg/ml) had significantly higher values compared to those without liver metastases (4.5 +/- 3.4 pg/ml; p = 0.001), without pleural effusions (5.45 +/- 1.5 pg/ml; p = 0.0077) and with dominant bone disease (4.5 +/- 1.4 pg/ml; p = 0.007) respectively. No correlation between sIL-6 and age, menopausal status, performance status, tumour grade, body-mass index, histology and hormone receptor status was found. Multivariate analysis showed that high levels of serum IL-6 have independent prognostic value. We conclude that circulating IL-6 is associated with worse survival in patients with metastatic breast cancer and is correlated with the extent of disease.
Collapse
Affiliation(s)
- Roberto Salgado
- Angiogenesis Group, Oncological Centre, A.Z. St.-Augustinus, Wilrijk-Antwerp, Belgium
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, van Dam P, Prové A, Lemmens J, Vermeulen P. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86:389-95. [PMID: 11875705 PMCID: PMC2375200 DOI: 10.1038/sj.bjc.6600069] [Citation(s) in RCA: 142] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2001] [Revised: 11/05/2001] [Accepted: 11/14/2001] [Indexed: 01/20/2023] Open
Abstract
Plasma levels of D-dimer are elevated in cancer patients. Activation of the extrinsic coagulation system and the fibrinolytic cascade within a tumour is thought to be related with growth, invasion and metastasis. We have investigated the relationship between these markers of fibrin metabolism, standard clinicopathological variables and serum levels of angiogenic cytokines in three cohorts: group A (n=30) consisted of 30 healthy female volunteers, group B (n=23) of consecutive patients with operable breast cancer and group C (n=84) of patients with untreated or progressive metastatic breast cancer. Plasma D-dimers, fibrinogen, IL-6, vascular endothelial growth factor and calculated vascular endothelial growth factor load in platelets are clearly increased in patients with breast cancer. D-dimers were increased in nearly 89% of patients with progressive metastatic disease. The level of D-dimers was positively correlated with tumour load (P<0.0001), number of metastatic sites (P=0.002), progression kinetics (P<0.0001) and the cytokines related to angiogenesis: serum vascular endothelial growth factor (P=0.0016, Spearman correlation=0.285), calculated vascular endothelial growth factor load in platelets (P<0.0001, Spearman correlation=0.37) and serum interleukin-6 (P<0.0001, Spearman correlation=0.59). Similarly increased D-dimer levels were positively correlated with increased fibrinogen levels (P<0.0001, Spearman correlation=0.38). The association between markers of fibrin degradation in patients with progressive breast cancer suggests that the D-dimer level is a clinically important marker for progression and points towards a relation between haemostasis and tumour progression. A role of interleukin-6, by influencing both angiogenesis and haemostasis, is suggested by these observations.
Collapse
Affiliation(s)
- Luc Y Dirix
- Oncology Center, AZ St-Augustinus Oosterveldlaan 24, 2610 Wilrijk, Belgium.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E, Dirix LY. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 1999; 80:892-7. [PMID: 10360671 PMCID: PMC2362300 DOI: 10.1038/sj.bjc.6690437] [Citation(s) in RCA: 128] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
We have compared the platelet number and the serum concentration of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and interleukin-6 (IL-6) in 80 blood samples of 50 patients with advanced cancer. We have also measured the mitogenic effect of patient sera on endothelial cells in vitro in order to estimate the biological activity of serum VEGF. Serum VEGF concentration correlated with platelet number (r = 0.61; P < 10(-4)). Serum IL-6 levels correlated with platelet count (r = 0.36; P < 10(-3)), with serum VEGF levels (r = 0.55; P < 10(-4)) and with the calculated load of VEGF per platelet (r = 0.4; P = 3 x 10(-4)). Patients with thrombocytosis had a median VEGF serum concentration which was 3.2 times higher (P < 10(-4)) and a median IL-6 serum level which was 5.8 times higher (P = 0.03) than in other patients. Serum bFGF did not show an association with any of the other parameters. Patient sera with high VEGF and bFGF content stimulated endothelial cell proliferation significantly more than other sera (P = 4 x 10(-3)). These results support the role of platelets in the storage of biologically active VEGF. Platelets seem to prevent circulating VEGF from inducing the development of new blood vessels except at sites where coagulation takes place. IL-6, besides its thrombopoietic effect, also seems to affect the amount of VEGF stored in the platelets. This is in accordance with the indirect angiogenic action of IL-6 reported previously. The interaction of IL-6 with the angiogenic pathways in cancer might explain the stimulation of tumour growth occasionally observed during IL-6 administration. It also conforms to the worse outcome associated with high IL-6 levels and with thrombocytosis in several tumour types and benign angiogenic diseases.
Collapse
Affiliation(s)
- R Salgado
- Angiogenesis Group, Oncological Centre, A.Z. St.-Camillus/St.-Augustinus, Wilrijk-Antwerp, Belgium
| | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
Thrombocytopenia is a major cause of morbidity following intensive chemotherapy for acute leukemia. Over recent years, there has been an increasing use of platelet transfusions which, although generally efficacious to prevent severe hemorrhage, have associated risks of transmitting blood-borne disease and of alloimmunization. Therefore, there is a clinical requirement for a drug that will reliably alleviate the thrombocytopenia associated with leukemia therapy. The c-mpl ligand thrombopoietin is the most interesting factor for the treatment of thrombocytopenia because of its lineage specificity. Phase I and II studies confirm its biological efficacy to induce rise in platelet count in patients with solid tumors and acute leukemia. Several other pleiotropic hematopoietic growth factors are also currently in clinical trials. These include interleukin-6, interleukin-3, interleukin-11, PIXY321 and stem cell factor. The effects of these cytokines appear to be modest at most and, with the exception of interleukin-11, their side effects are likely to limit their clinical application. Combinations of factors may prove more efficacious approaches to enhance platelet recovery.
Collapse
Affiliation(s)
- E Archimbaud
- Service d'Hématologie, Hôpital Edouard Herriot, Lyon, France
| | | |
Collapse
|
23
|
Abstract
At least 20 different hematopoietic drugs (see Table 1) are currently under investigation. These most likely will impact on all aspects of transfusion therapy. Which agents to use and in what combinations will be the subject of scrutiny for many years to come as scientists try to recreate and enhance the process of hematopoiesis. Perhaps someday blood cells and hematopoietic progenitor cells can be manufactured for therapy with genetically selected phenotypes to avoid immune destruction and rejection. If this comes to pass, blood donations as we know them today, as a valuable adjunct to medical care, will fade into history, supplanted by the use of hematopoietic growth factors.
Collapse
Affiliation(s)
- G Ramsey
- Department of Pathology, Northwestern University Medical School, Chicago, IL, USA
| |
Collapse
|